Home   Logon   Mobile Site   Research and Commentary   About Us   Call 1.800.621.1675 or Email Us       Follow Us: 

Search by Ticker, Keyword or CUSIP       
 
 
 
Blog Home
Jeff Margolin
Closed-End Fund Analyst
Click for Bio

Follow Jeff on LinkedIn
Ryan Issakainen
ETF Strategist
Click for Bio

Follow Ryan on LinkedIn
 

  How Have Presidential Elections Impacted Biotechnology Stocks?
Posted Under: ETFs

 
Biotechnology stocks had a stellar start to 2020, showing great resilience as investors pinned their hopes on the industry to produce new COVID-19 vaccines and therapeutics.  As we discussed earlier this year, the pandemic may also bring about important long-term benefits for the industry, including more efficient regulation, increased mergers and acquisitions (M&A) activity, and an improved public image.

However, since peaking on July 20th, the NYSE Arca Biotechnology Index has declined by 12.7%, while the S&P 500 Index has advanced by 8.7% (through 9/1/20).  While there are many possible explanations for biotech's recent underperformance, I believe one important factor is the upcoming presidential election.  Rising health care costs in the U.S. have been a go-to wedge issue for Democratic party candidates in election campaigns, especially over the past two decades (Affordable Care Act passed in 2010).  But if history repeats, this pullback may represent an attractive buying opportunity.

During the last four presidential elections (2004, 2008, 2012, and 2016), biotechnology stocks performed poorly heading into election day. On average, the NYSE Arca Biotechnology Index had a -6.4% return during the prior 2 months (see chart above).  However, biotech stocks also rebounded nicely following these elections, regardless of which candidate was elected.  While Democratic and Republican presidential candidates split these four elections evenly, the average return 2 months after election day was 4.8%, and the average return 12 months after election day was 34.5%.

The link between biotech stocks and politics is nothing new, and recent weakness substantiates that point.  But investors that can look past election day—or take advantage of weakness leading up to it—may be rewarded.

Click Here to continue reading.
Posted on Friday, September 4, 2020 @ 8:24 AM • Post Link Share: 
Print this post Printer Friendly

These posts were prepared by First Trust Advisors L.P., and reflect the current opinion of the authors. They are based upon sources and data believed to be accurate and reliable. Opinions and forward looking statements expressed are subject to change without notice. This information does not constitute a solicitation or an offer to buy or sell any security.
Search Posts
INVESTMENT INSIGHTS


 PREVIOUS POSTS
Asset Flows Monitor August 2020 Edition
Factors Align For Post-Pandemic 5G Growth
Alternatives Update 2nd Quarter 2020
Navigating a Pandemic with Thematic ETFs
Asset Flows Monitor July 2020 Edition
The Post-Pandemic Opportunity for Biotech
Asset Flows Monitor June 2020 Edition
As Dividends Become Scarcer, Will they Become More Valued?
Asset Flows Monitor May 2020 Edition
Alternatives Update 1st Quarter 2020
Archive
Skip Navigation Links.
Search by Topic
Skip Navigation Links.

 
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
First Trust Portfolios L.P.  Member SIPC and FINRA. (Form CRS)   •  First Trust Advisors L.P. (Form CRS)
Home |  Important Legal Information |  Privacy Policy |  California Privacy Policy |  Business Continuity Plan |  FINRA BrokerCheck
Copyright © 2021 All rights reserved.